review of literature on clinical pancreatology - The Pancreapedia

374. Son K, Fujioka S, Iida T, Furukawa K, Fujita T, Yamada H, Chiao PJ, Yanaga K. Doxycyclineinduces apoptosis in PANC-1 pancreatic cancer cells. Anticancer Res 2009; 29: 3995-4003.375. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptorinhibitors. Clin Cancer Res 2009; 15: 1133-9.376. Cates JMM, Byrd RH, Fohn LE, Tatsas AD, Washington MK, Black CC. Epithelial-mesenchymaltransition markers in pancreatic ductal adenocarcinoma. Pancreas 2009; 38: e1-6.377. Guo QQ, Zhang B, Dong X, Xie QP, Guo EQ, Huang H, Wu Y. Elevated levels <strong>of</strong> plasmafibrinogen in patients with pancreatic cancer: possible role <strong>of</strong> a distant metastasis predictor. Pancreas2009; 38: e75-9.378. Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY,Billadeau DD, Kozikowski AP. From a natural product lead to the identification <strong>of</strong> potent and selectivebenz<strong>of</strong>uran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppressproliferation and survival <strong>of</strong> pancreatic cancer cells. J Med Chem 2009; 52: 1853-63.379. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Eng J Med 2009; 361:2094-6.380. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased inchronic pancreatitis and pancreatic carcinoma. Pancreas 2009; 38: 422-6.381. Maréchal R, Van Laethem JL. HuR modulates gemcitabine efficacy: new perspectives inpancreatic cancer treatment. Expert Rev Anticancer Ther 2009; 9: 1439-41.382. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics:novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer DrugDiscov 2009; 4: 54-72.383. Walsh N, Clynes M, Crown J, O'Donovan N. Alterations in integrin expression modulates invasion<strong>of</strong> pancreatic cancer cells. J Exp Clin Cancer Res 2009; 28: 140.384. Fujisawa T, Joshi B, Nakajima A, Puri RK. A novel role <strong>of</strong> interleukin-13 receptor alpha2 inpancreatic cancer invasion and metastasis. Cancer Res 2009; 69: 8678-85.385. Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E,DePinho RA, Jacks T. Context-dependent transformation <strong>of</strong> adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009; 16: 379-89.386. Ji Z, Mei FC, Lory PL, Gilbertson SR, Chen Y, Cheng X. Chemical genetic screening <strong>of</strong> KRASbasedsynthetic lethal inhibitors for pancreatic cancer. Front Biosci 2009; 14: 2904-10.387. Uhland K, Siphos B, Arkona C, Schuster M, Petri B, Steinmetzer P, Mueller F, Schweinitz A,Steinmetzer T, Van De Locht A. Use <strong>of</strong> IHC and newly designed matriptase inhibitors to elucidate therole <strong>of</strong> matriptase in pancreatic ductal adenocarcinoma. Int J Oncol 2009; 35: 347-57.388. Mizutani S, Miyato Y, Shidara Y, Asoh S, Tokunaga A, Tajiri T, Ohta S. Mutations in themitochondrial genome confer resistance <strong>of</strong> cancer cells to anticancer drugs. Cancer Sci 2009 Jun 1[Epub ahead <strong>of</strong> print].389. Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation <strong>of</strong>nuclear factor-kappaB. Mol Cancer Res 2009; 7: 624-33.390. Chipitsyna G, Gong Q, Anandanadesan R, Alnajar A, Batra SK, Wittel UA, Cullen DM, AkhterMP, Denhardt DT, Yeo CJ, Arafat HA. Induction <strong>of</strong> osteopontin expression by nicotine and cigarettesmoke in the pancreas and pancreatic ductal adenocarcinoma cells. Int J Cancer 2009; 125: 276-85.